AbbVie Inc. (ABBV)

NYSE: ABBV · USD

$286

-0.29 (-0.1%)· Recorded snapshot

Engelse bronNL

Engelse bron wordt weergegeven terwijl we vertalen

Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.

StockMarketAgent Research · Analyzed 2026-09-08

Our latest published analysis: ABBV rated Sell

AbbVie Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$180 / share

Potential value

$251 / share

Upside to FV

-29.8%

from $286

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$453.2B
Revenue (ttm)	64.4B
Net income (ttm)	6.3B
EPS (ttm)	$3.54
Shares out	1.8B
P/E (trailing)	80.8x
P/E (forward)	16.1x
Dividend	$6.92 (2.42%)
Volume	1,928,807
Beta	0.23

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 64.4B
Net income (ttm): 6.3B
EPS (ttm): $3.54
P/E (trailing): 80.8x
P/E (forward): 16.1x
Market cap: $453.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$56.20B	$58.05B	$54.32B	$56.33B	$61.16B	+2.1%
Gross profit	$10.57B	$10.95B	$8.60B	$10.71B	$12.07B	+3.4%
Operating income	$17.92B	$18.12B	$12.76B	$9.14B	$15.08B	-4.2%
Net income	$11.54B	$11.84B	$4.86B	$4.28B	$4.23B	-22.2%
EPS (diluted)	$6.45	$6.63	$2.72	$2.39	$2.36	-22.2%
EBITDA	$23.93B	$24.17B	$17.17B	$14.91B	$17.63B	-7.4%
R&D	$8.05B	$6.51B	$7.68B	$12.79B	$9.10B	+3.1%
SG&A	$12.35B	$15.26B	$12.87B	$14.75B	$14.01B	+3.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Verminderen
ACN	Accenture plc	144.3B	18.0x	2.0x	27.9%	+8.0%	+0.4%	Aanhouden
ADI	Analog Devices, Inc.	207.6B	50.9x	14.8x	11.0%	+16.4%	+76.9%	Verkopen
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Verminderen
ALNY	Alnylam Pharmaceuticals, Inc.	31.1B	41.4x	6.4x	96.6%	+47.5%	-52.1%	Sterk kopen
AMGN	Amgen Inc.	244.2B	28.1x	6.4x	19.8%	+8.4%	+58.6%	Kopen

Base and Bull scenarios

Base55%

Price target

$180.11

-29.8% from spot

The base case remains modal because annual estimates support recovery. It would weaken if growth faded faster after FY2027 or if less revenue became adjusted earnings.

FY2027 revenue and adjusted EPS remain near their dated means.
The base path assumes growth fades after FY2027, operating margins stay broadly stable, and the share count does not rise materially. These are forward assumptions, not observed trends.

Bull20%

Price target

$250.84

-2.2% from spot

This path needs sustained earnings growth after the explicit estimate period. A rapid mature-growth fade would disconfirm it.

FY2027 revenue and adjusted EPS approach the upper ends of their estimate ranges.
Strong conversion persists beyond FY2027 without meaningful dilution.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($180.11). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.0%	1.5%	2.0%	2.5%	3.0%
5.2%	$217	$235	$258	$290	$336
6.2%	$183	$194	$207	$224	$246
7.2%	$158	$166	$180	$185	$198
8.2%	$140	$146	$151	$158	$167
9.2%	$126	$130	$134	$139	$145

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E16.1

P25 n/aP50 n/aP75 n/a

Trailing P/E72.5

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC17.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ABBV indicators

Market & fundamental data

Available fields

279

Groups with data

Currency

USD

Showing 279 of 279 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001551152
Company name	AbbVie Inc.
Country	United States
Country code	US
CUSIP number	00287Y109
Earnings date	2026-10-30
Earnings time	bmo
Employees	57,000
Employees change	2,000
Employees growth	3.64%
Enterprise value	$569.9B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
In index	SP500
Industry	Drug Manufacturers - General
Is primary listing	Yes
Is SPAC	No
ISIN number	US00287Y1091
Last 10-K release date	2026-02-20
Last earnings date	2026-07-31
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$505.6B
Market cap category	Mega-Cap
Next earnings date	2026-10-30
Options	Yes
Price	$286.09
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ABBV
U.S. state	Illinois
Website	https://www.abbvie.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	26.32x
Average P/E ratio (10Y)	41.3x
Average P/E ratio (3Y)	81.44x
Average P/E ratio (5Y)	58.76x
Earnings yield	1.24%
EV/Earnings	91.58x
EV/EBIT	25.08x
EV/EBITDA	18.67x
EV/FCF	31.53x
EV/Sales	8.92x
FCF / EV yield	3.17%
FCF yield	3.57%
Forward EV/Sales	8.2x
Forward P/E	19.01x
Forward P/S	7.28x
Industry forward P/E	18.47x
Industry P/E	35.8x
Lynch fair value	$17.70
Lynch upside	-93.87%
P/(FCF - SBC) ratio	29.59x
P/(OCF - SBC) ratio	27.52x
P/E ratio	80.82x
P/FCF ratio	28x
P/OCF ratio	26.14x
P/S ratio	7.92x
PEG ratio	1.41x
Price/EBITDA ratio	16.58x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	35.56%
EBITDA margin	47.78%
Effective tax rate	27.39%
FCF margin	28.28%
Gross margin	72.79%
Operating margin	35.56%
Pretax margin	13.51%
Profit margin	9.8%
Profit per employee	$110,000
Profitable quarters	6
Profitable years	17
Revenue per employee	$1.1M
ROA	10.51%
ROA (5Y)	8.68%
ROCE	24.49%
ROE (5Y)	1,295.17%
ROIC	17.7%
ROIC (5Y)	21.99%
SBC / revenue	1.52%
Tax / revenue	3.7%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	68.54%
EPS growth (Q)	290.39%
EPS growth (QoQ)	422.72%
EPS growth 10Y	0.21%
EPS growth 3Y	-10.05%
EPS growth 5Y	-0.92%
EPS growth quarters	1
EPS growth years	0
FCF growth	-0.16%
FCF growth (Q)	-36.24%
FCF growth (QoQ)	-12.63%
FCF growth 3Y	-9.78%
FCF growth 5Y	-1.43%
Gross profit growth	12.78%
Gross profit growth (Q)	14.64%
Gross profit growth 3Y	5.88%
Gross profit growth 5Y	5.07%
Net income growth	67.69%
Net income growth (Q)	285.18%
Net income growth (QoQ)	424.16%
Net income growth 3Y	-10.12%
Net income growth 5Y	-1.02%
Net income growth quarters	1
Net income growth years	0
OCF growth	1.16%
OCF growth (Q)	-33.32%
OCF growth (QoQ)	-10.26%
OCF growth 10Y	9.1%
OCF growth 3Y	-8.59%
OCF growth 5Y	-0.94%
Operating income growth	21.17%
Operating income growth (Q)	17.54%
Operating income growth 3Y	3.56%
Operating income growth 5Y	3.75%
Revenue growth	10.39%
Revenue growth (Q)	10.16%
Revenue growth (QoQ)	13.25%
Revenue growth 10Y	10.03%
Revenue growth 3Y	4.75%
Revenue growth 5Y	3.69%
Revenue growth quarters	10
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.3B
Depreciation and amortization	$7.9B
EBIT	$22.9B
EBITDA	$30.8B
EPS	$3.54
FCF per share	$10.30
Financing cash flow	$-12.9B
Free cash flow	$18.2B
Free cash flow minus SBC	$17.2B
Gross profit	$46.9B
Income taxes	$2.4B
Investing cash flow	$-6.5B
Net borrowing	$418M
Net cash flow	$102M
Net income	$6.3B
Operating cash flow minus SBC	$18.5B
Operating income	$22.9B
Revenue	$64.4B
Stock-based compensation	$976M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.42
Book value per share	$-3.36
Debt / EBITDA	2.28
Debt / FCF	3.89
Goodwill	$35.5B
Interest coverage	7.85
Long-term assets	$101.4B
Long-term liabilities	$99.4B
Net cash (debt)	$-64.3B
Net cash / market cap	-12.61%
Net debt / EBITDA	2.09
Net debt / FCF	3.53
Piotroski F-Score	8
Property, plant and equipment	$5.8B
Shareholders' equity	$-5.9B
Tangible book value	$-90.6B
Tangible book value per share	$-51.27
Total assets	$135.1B
Total cash	$6.6B
Total debt	$70.9B
Total liabilities	$141B
WACC	5.2%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.47
Current assets	$33.7B
Current liabilities	$41.6B
Current ratio	0.81
Inventory turnover	3.47
Net working capital	$-6.2B
Quick ratio	0.49
Working capital	$-8B
Working capital turnover	-6.97

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.03%
Dividend growth	5.49%
Dividend growth (10Y)	11.74%
Dividend growth (3Y)	5.34%
Dividend growth (5Y)	5.88%
Dividend growth years	54
Dividend payment date	2026-11-16
Dividend payment years	54
Dividend payout frequency	Quarterly
Dividend per share	$6.92
Dividend yield	2.42%
Ex-dividend date	2026-10-15
FCF payout ratio	67.15%
Last dividend	$1.73
Payout ratio	195.5%
Shareholder yield	2.37%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	365.21%
10Y return CAGR	21.47%
10Y total return	599.16%
150-day SMA	$241.11
1D price change	-0.1%
1M price change	8.16%
1M total return	8.83%
1W price change	-1.09%
1W total return	-1.09%
1Y price change	25.39%
1Y return CAGR	29.16%
1Y total return	29.14%
20-day SMA	$278.48
200-day SMA	$236.38
3M price change	11.29%
3M total return	11.98%
3Y price change	105.8%
3Y return CAGR	31.49%
3Y total return	127.39%
50-day SMA	$268.13
50-day SMA vs 200-day SMA	50over200
52-week high	$291.40
52-week high date	2026-10-15
52-week low	$190.75
52-week low date	2026-04-29
5Y price change	163.76%
5Y return CAGR	25.8%
5Y total return	215.02%
6M price change	44.86%
6M total return	46.78%
All-time high	$291.40
All-time high date	2026-10-15
All-time low	$32.51
All-time low date	2012-12-17
Average true range (ATR)	$6.25
Average volume	5.1M
Beta (1Y)	-0.71
Beta (2Y)	0.05
Beta (5Y)	0.23
Change from 52-week high	-1.82%
Change from 52-week low	49.98%
Change from all-time high	-1.88%
Change from all-time low	779.48%
Change from open	1.34%
Day's gap	-1.42%
Dollar volume	$551.8M
High price	$288.66
Low price	$281.23
Monthly RSI	74.08
Open price	$282.31
Position in 52-week range	65.41%
Premarket change	-1.01%
Premarket close	$286.39
Premarket price	$283.50
Premarket volume	4.2K
Previous close	$286.39
Price vs 150-day SMA	18.58%
Price vs 20-day SMA	2.67%
Price vs 200-day SMA	20.96%
Price vs 50-day SMA	6.63%
Relative volume	0.38
RSI	64.59
Sharpe ratio	0.97
Sharpe ratio (3Y)	1.02
Sharpe ratio (5Y)	0.93
Sortino ratio	1.72
Sortino ratio (3Y)	1.67
Sortino ratio (5Y)	1.55
Volume	1.9M
Weekly RSI	72.61
YTD price change	25.14%
YTD total return	28.88%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.8B
Float percentage	99.82%
Shares change (QoQ)	-0.23%
Shares change (YoY)	0.03%
Shares held by insiders	0.07%
Shares held by institutions	76.58%
Shares outstanding	1.8B
Short % of float	0.92%
Short % of shares	0.92%
Short ratio	3.9 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	382

Deeper analysis on ABBV

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this ABBV report

What is the latest published ABBV stock rating?

AbbVie Inc. is shown with Sell in the latest published report, analyzed 2026-09-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ABBV analysis?

The full latest published report, analyzed 2026-09-08, lives at /stocks/ABBV/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for ABBV?

The latest published report analyzed 2026-09-08 gives ABBV a fair value of USD 180 and a potential value of USD 251. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the ABBV page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

SellABBV · Fair value $180-29.8%

Read full analysis →

AbbVie Inc. (ABBV)

Our latest published analysis: ABBV rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · ABBV

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All ABBV indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on ABBV

Frequently asked questions

Ratinggeschiedenis

Category	Score	Reading
Valuation	1.5
Management	6.5
Balance Sheet	3.0
Profitability	7.0
Revenue Growth	6.0
Risk Assessment	5.5
Competitive Moat	1.0
Earnings Quality	9.0
Capital Efficiency	7.5